Lenalidomide as an important drug in hematologic malignancies

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F19%3A00012798" target="_blank" >RIV/00023736:_____/19:00012798 - isvavai.cz</a>
Result on the web
<a href="https://novapublishers.com/shop/advances-in-medicine-and-biology-volume-150/" target="_blank" >https://novapublishers.com/shop/advances-in-medicine-and-biology-volume-150/</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Lenalidomide as an important drug in hematologic malignancies
Original language description
The authors go on to discuss lenalidomide, a chemical analog of thalidomide and a member of the group of immunomodulatory or cereblon-binding drugs. Lenalidomide has antineoplastic, antiproliferative, antiangiogenic, anti-inflammatory, pro-erythropoieic, and immunomodulatory properties. Lenalidomide binds to a specific hydrophobic pocket in the protein cereblon. This pocket is coded by the exons 10 and 11 on the C-end of cereblon gene. Cereblon interacts with the DNA damage-binding protein-1, cullin 4, and regulator of cullins 1 to form the E3 ubiquitin ligase complex. Lenalidomide also enhances the antitumor effect of chimeric antigen receptor modified T cells in murine models of aggressive B-cell non-Hodgkin lymphoma. Lenalidomide has also been studied in the treatment of cutaneous manifestations of systemic lupus erythematosus and neurodegenerative disorders connected with neuroinflammation, such as amyotrophic lateral sclerosis.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)